{"id":"early-dual-iv-antibiotic-therapy-mssa","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity (aminoglycoside-related)"},{"rate":null,"effect":"Ototoxicity (aminoglycoside-related)"},{"rate":null,"effect":"Hypersensitivity reactions (beta-lactam-related)"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL5984914","moleculeType":null,"molecularWeight":"296.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a clinical treatment protocol rather than a single drug entity. It combines two IV antibiotics (typically a beta-lactam such as nafcillin or oxacillin with an aminoglycoside or fluoroquinolone) to provide synergistic bactericidal activity against MSSA. The dual approach aims to improve clinical outcomes, reduce mortality, and minimize the emergence of antibiotic resistance compared to monotherapy.","oneSentence":"Early dual IV antibiotic therapy uses two intravenous antibiotics simultaneously to treat methicillin-sensitive Staphylococcus aureus (MSSA) infections with broader coverage and reduced resistance risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:01.402Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia and serious infections"},{"name":"MSSA endocarditis"},{"name":"MSSA pneumonia"}]},"trialDetails":[{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["cefazolin","ertapenem","rifampin"],"phase":"marketed","status":"active","brandName":"Early Dual IV Antibiotic Therapy - MSSA","genericName":"Early Dual IV Antibiotic Therapy - MSSA","companyName":"West Virginia University","companyId":"west-virginia-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Early dual IV antibiotic therapy uses two intravenous antibiotics simultaneously to treat methicillin-sensitive Staphylococcus aureus (MSSA) infections with broader coverage and reduced resistance risk. Used for Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia and serious infections, MSSA endocarditis, MSSA pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}